2.22 USD
-0.11 (-4.72%)
2.22 USD
0 (0%)
We assign a fundamental rating of 3 out of 10 to CCCC. CCCC was compared to 528 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CCCC as it has an excellent financial health rating, but there are worries on the profitability. CCCC is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year CCCC has reported negative net income.
- CCCC had a negative operating cash flow in the past year.
- CCCC had negative earnings in each of the past 5 years.
- In the past 5 years CCCC always reported negative operating cash flow.
1.2 Ratios
- With a Return On Assets value of -44.85%, CCCC perfoms like the industry average, outperforming 55.11% of the companies in the same industry.
- CCCC has a Return On Equity (-77.12%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.85% | ||
| ROE | -77.12% | ||
| ROIC | N/A |
ROA(3y)-31.69%
ROA(5y)-25.64%
ROE(3y)-48.97%
ROE(5y)-38.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- CCCC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- CCCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
- CCCC has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for CCCC has been increased compared to 5 years ago.
- CCCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- CCCC has an Altman-Z score of -3.22. This is a bad value and indicates that CCCC is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -3.22, CCCC is in line with its industry, outperforming 45.45% of the companies in the same industry.
- There is no outstanding debt for CCCC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.22 |
ROIC/WACCN/A
WACC8.79%
2.3 Liquidity
- CCCC has a Current Ratio of 5.76. This indicates that CCCC is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of CCCC (5.76) is better than 60.04% of its industry peers.
- A Quick Ratio of 5.76 indicates that CCCC has no problem at all paying its short term obligations.
- CCCC has a Quick ratio of 5.76. This is in the better half of the industry: CCCC outperforms 61.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.76 | ||
| Quick Ratio | 5.76 |
3. Growth
3.1 Past
- CCCC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.91%.
- The Revenue for CCCC has decreased by -10.57% in the past year. This is quite bad
- Measured over the past years, CCCC shows a quite strong growth in Revenue. The Revenue has been growing by 10.73% on average per year.
EPS 1Y (TTM)2.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.71%
Revenue 1Y (TTM)-10.57%
Revenue growth 3Y-8.06%
Revenue growth 5Y10.73%
Sales Q2Q%-26.9%
3.2 Future
- Based on estimates for the next years, CCCC will show a very strong growth in Earnings Per Share. The EPS will grow by 33.06% on average per year.
- Based on estimates for the next years, CCCC will show a very strong growth in Revenue. The Revenue will grow by 96.69% on average per year.
EPS Next Y-4.99%
EPS Next 2Y1.6%
EPS Next 3Y5.06%
EPS Next 5Y33.06%
Revenue Next Year-12.79%
Revenue Next 2Y-22.73%
Revenue Next 3Y-15.45%
Revenue Next 5Y96.69%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for CCCC. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CCCC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.6%
EPS Next 3Y5.06%
5. Dividend
5.1 Amount
- No dividends for CCCC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
2.22
-0.11 (-4.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-01 2025-10-01/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners67.15%
Inst Owner Change0%
Ins Owners1.69%
Ins Owner Change2%
Market Cap215.14M
Revenue(TTM)30.11M
Net Income(TTM)-119.08M
Analysts85.71
Price Target11.37 (412.16%)
Short Float %8.49%
Short Ratio4.16
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.34%
Min EPS beat(2)-6.21%
Max EPS beat(2)5.54%
EPS beat(4)2
Avg EPS beat(4)4.54%
Min EPS beat(4)-6.21%
Max EPS beat(4)19.39%
EPS beat(8)4
Avg EPS beat(8)5.54%
EPS beat(12)6
Avg EPS beat(12)5.68%
EPS beat(16)9
Avg EPS beat(16)8.22%
Revenue beat(2)1
Avg Revenue beat(2)36.02%
Min Revenue beat(2)-3.26%
Max Revenue beat(2)75.3%
Revenue beat(4)2
Avg Revenue beat(4)32.63%
Min Revenue beat(4)-3.26%
Max Revenue beat(4)75.3%
Revenue beat(8)5
Avg Revenue beat(8)55.13%
Revenue beat(12)6
Avg Revenue beat(12)31.97%
Revenue beat(16)8
Avg Revenue beat(16)37.82%
PT rev (1m)-6.02%
PT rev (3m)-25.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.58%
EPS NY rev (1m)-1.59%
EPS NY rev (3m)3.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.32%
Revenue NY rev (1m)-3.19%
Revenue NY rev (3m)15.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.15 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.39 | ||
| P/tB | 1.39 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.67
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS0.31
BVpS1.59
TBVpS1.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.85% | ||
| ROE | -77.12% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-31.69%
ROA(5y)-25.64%
ROE(3y)-48.97%
ROE(5y)-38.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 29.44% | ||
| Cap/Sales | 1.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.76 | ||
| Quick Ratio | 5.76 | ||
| Altman-Z | -3.22 |
F-Score3
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)142.71%
Cap/Depr(5y)110.83%
Cap/Sales(3y)8.81%
Cap/Sales(5y)6.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.71%
EPS Next Y-4.99%
EPS Next 2Y1.6%
EPS Next 3Y5.06%
EPS Next 5Y33.06%
Revenue 1Y (TTM)-10.57%
Revenue growth 3Y-8.06%
Revenue growth 5Y10.73%
Sales Q2Q%-26.9%
Revenue Next Year-12.79%
Revenue Next 2Y-22.73%
Revenue Next 3Y-15.45%
Revenue Next 5Y96.69%
EBIT growth 1Y-1.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.98%
EBIT Next 3Y-15.22%
EBIT Next 5YN/A
FCF growth 1Y17.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.61%
OCF growth 3YN/A
OCF growth 5YN/A
C4 THERAPEUTICS INC / CCCC FAQ
What is the fundamental rating for CCCC stock?
ChartMill assigns a fundamental rating of 3 / 10 to CCCC.
What is the valuation status of C4 THERAPEUTICS INC (CCCC) stock?
ChartMill assigns a valuation rating of 0 / 10 to C4 THERAPEUTICS INC (CCCC). This can be considered as Overvalued.
Can you provide the profitability details for C4 THERAPEUTICS INC?
C4 THERAPEUTICS INC (CCCC) has a profitability rating of 1 / 10.
How financially healthy is C4 THERAPEUTICS INC?
The financial health rating of C4 THERAPEUTICS INC (CCCC) is 7 / 10.
What is the earnings growth outlook for C4 THERAPEUTICS INC?
The Earnings per Share (EPS) of C4 THERAPEUTICS INC (CCCC) is expected to decline by -4.99% in the next year.